Minerva Neurosciences   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2007)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2014
NCT02232529
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Minerva Neurosciences

Active Ingredients

Drugs in Phase 3 Trials (1)

roluperidone (5 trials)

Drugs in Phase 2 Trials (2)

min-117 (1 trial)

seltorexant (2 trials)

Drugs in Phase 1 Trials (1)

olanzapine (zyprexa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4